Objective To investigate the completeness and currency of published systematic reviews of
remdesivir for COVID-19 and to compare this with a living guidelines approach. Study …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral
pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical …

Aims Remdesivir is 1 of the repurposed drugs under investigation to treat patients with
COVID‐19. Clinicians and decision‐makers need a summary of the most recent evidence …

Background This critical appraisal aims to clarify which systematic reviews on COVID‐19
treatment are based on high‐value evidence. Hereby, the most profitable medicines can be …

Introduction Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking
RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic …

Background COVID-19 is an ongoing viral pandemic produced by SARS-CoV-2. In light of in
vitro efficacy, several medications were repurposed for its management. During clinical use …

Coronavirus disease (COVID-19) is the current global public health concern. To date, no
specific, effective, and approved treatment is available. With the rapid increase in the rate of …

Since the first detection of a cluster of COVID-19 patients in China in late 2019, it becomes a
global concern due to its transmissibility and ability to progress patients in severe respiratory …

Abstract Background and Aims During the COVID‐19 pandemic, US Food and Drug
Administration (FDA) permitted emergency use authorizations (EUAs) for …

Since the beginning of the SARS-CoV-2 pandemic, the treatments and management of the
deadly COVID-19 disease have made great progress. The strategies for developing novel …